Recent research on the application of biologics in the treatment of multisystem inflammatory syndrome in children after SARS-CoV-2 infection
DOI:
CSTR:
Author:
Affiliation:

Clc Number:

S85

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Multisystem inflammatory syndrome in children(MIS-C)is a type of hyperinflammatory symptoms similar to Kawasaki disease after severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection and is commonly observed in children aged 8-10 years.Primary therapeutic medications for MIS-C are intravenous immunoglobulins and glucocorticoids.It has been reported that biologics,such as IL-1 receptor antagonist anakinra,IL-6 receptor antagonist tocilizumab,and TNF-αreceptor antagonist infliximab,can be used as an option for critically ill patients.This article elaborates on the mechanism of action of the above biologics and discusses the efficacy and safety biologics in the treatment of MIS-C after SARS-CoV-2 infection,in order to provide methods for the treatment of MIS-C with severe symptoms.

    Reference
    Related
    Cited by
Get Citation

崔涵雨(综述),胡长平,罗平(审校).生物制剂在儿童感染SARS-CoV-2后多系统炎症综合征的应用研究进展[J].中国当代儿科杂志英文版,2022,(2):216-222

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:November 03,2021
  • Revised:
  • Adopted:
  • Online: August 02,2023
  • Published:
Article QR Code